Antonio Giordano/X
Aug 22, 2025, 12:02
Antonio Giordano Presents the Results of TRADE Trial
Antonio Giordano, Breast Medical Oncologist at Dana-Farber Cancer Institute, shared a post by DAVA Oncology on X, adding:
”A privilege to present the results of TRADE trial. Initial dose escalation strategy (50-100-150) for adjuvant abemaciclib allowed a greater number of patients to reach and maintain 150 mg BID dosing at 12-weeks than observed in monarchE.”
Quoting DAVA Oncology’s post:
”Dr. Antonio Giordan from Dana-Farber shares TRADE trial data: 70.8% of patients with early-stage HR+/HER2- BC reached and maintained 150mg BID abemaciclib at 12 weeks using a dose-escalation strategy. Toxicities were manageable, with low discontinuation for adverse events.”
More posts featuring Antonio Giordano.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Aug 22, 2025, 12:02
Aug 22, 2025, 11:57
Aug 22, 2025, 11:54
Aug 22, 2025, 11:44
Aug 22, 2025, 11:36
Aug 22, 2025, 11:25
Aug 22, 2025, 11:06